XML 70 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Contract with Customer, Liability $ 175,646 $ 171,516
U.S./RoW and China [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 1,064,217  
Contract with Customer, Liability 175,646  
Total Consideration 1,239,863  
U.S./RoW and China [Member] | License Revenue [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 341,844  
Contract with Customer, Liability 0  
Total Consideration 341,844  
U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 615,639  
Contract with Customer, Liability 0  
Total Consideration 615,639  
U.S./RoW and China [Member] | China performance obligation [Member]    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Cumulative Revenue 106,734  
Contract with Customer, Liability 175,646  
Total Consideration $ 282,380